Published in Addiction on May 01, 1998
Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry (2004) 3.72
Behavioral therapies for drug abuse. Am J Psychiatry (2005) 2.75
Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction (2013) 2.42
The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J Consult Clin Psychol (2006) 2.31
The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend (2006) 2.30
Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs (2009) 1.94
Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data. Drug Alcohol Depend (2002) 1.45
Clinical care of the HIV-infected drug user. Infect Dis Clin North Am (2007) 1.30
One small step for manuals: Computer-assisted training in twelve-step facilitation. J Stud Alcohol (2006) 1.29
Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend (2004) 1.28
Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. Proc Natl Acad Sci U S A (2002) 1.27
Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase. Neuropsychopharmacology (2010) 1.27
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol Psychiatry (2012) 1.27
Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend (2007) 1.26
The search for medications to treat stimulant dependence. Addict Sci Clin Pract (2008) 1.25
mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv (2009) 1.23
Norepinephrine and stimulant addiction. Addict Biol (2008) 1.21
Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) (2005) 1.20
Perspective is everything: the predictive validity of six working alliance instruments. J Psychother Pract Res (2001) 1.16
Treatment process, alliance and outcome in brief versus extended treatments for marijuana dependence. Addiction (2010) 1.12
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav (2007) 1.11
Therapist predictors of treatment delivery fidelity in a community-based trial of 12-step facilitation. Am J Drug Alcohol Abuse (2013) 1.11
Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med (2011) 1.10
Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depend (2014) 1.10
Ethnic differences in substance abuse treatment retention, compliance, and outcome from two clinical trials. Psychiatr Serv (2004) 1.10
Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care (2011) 1.09
Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend (2006) 1.09
Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend (2010) 1.08
Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacol Ther (2009) 1.08
Neurobiological dissociation of retrieval and reconsolidation of cocaine-associated memory. J Neurosci (2013) 1.07
Conditioned place preference for social interaction in rats: contribution of sensory components. Front Behav Neurosci (2011) 1.05
Evidence-based practices for substance use disorders. Psychiatr Clin North Am (2003) 1.05
Stimulant abuser groups to engage in 12-step: a multisite trial in the National Institute on Drug Abuse Clinical Trials Network. J Subst Abuse Treat (2012) 1.04
Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther (2012) 1.04
Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am J Drug Alcohol Abuse (2007) 1.02
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse (2009) 1.02
Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology (2011) 1.00
Behavioral therapies for co-occurring substance use and mood disorders. Biol Psychiatry (2004) 0.97
Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat (2014) 0.95
Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug Alcohol Depend (2012) 0.94
Psychological interventions for antisocial personality disorder. Cochrane Database Syst Rev (2010) 0.94
Assessing fidelity of treatment delivery in group and individual 12-step facilitation. J Subst Abuse Treat (2012) 0.92
The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. PLoS One (2012) 0.92
Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One (2014) 0.90
Treatment of co-occurring alcohol and other drug use disorders. Alcohol Res Health (2008) 0.90
LC-MS/MS determination of carbamathione in microdialysis samples from rat brain and plasma. J Pharm Biomed Anal (2009) 0.90
Inhibition of hippocampal β-adrenergic receptors impairs retrieval but not reconsolidation of cocaine-associated memory and prevents subsequent reinstatement. Neuropsychopharmacology (2013) 0.90
A general method for handling missing binary outcome data in randomized controlled trials. Addiction (2014) 0.90
How practice and science are balanced and blended in the NIDA Clinical Trials Network: the bidirectional process in the development of the STAGE-12 protocol as an example. Am J Drug Alcohol Abuse (2011) 0.89
Disulfiram stimulates dopamine release from noradrenergic terminals and potentiates cocaine-induced dopamine release in the prefrontal cortex. Psychopharmacology (Berl) (2011) 0.89
Does treatment fidelity predict client outcomes in 12-Step Facilitation for stimulant abuse? Drug Alcohol Depend (2013) 0.89
A Combined Group and Individual 12-Step Facilitative Intervention Targeting Stimulant Abuse in the NIDA Clinical Trials Network: STAGE-12. J Groups Addict Recover (2011) 0.88
Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry (2010) 0.88
Sex differences in cocaine-dependent individuals' response to disulfiram treatment. Addict Behav (2004) 0.88
Biomarkers for the development of new medications for cocaine dependence. Neuropsychopharmacology (2013) 0.87
Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Rev Clin Pharmacol (2014) 0.87
Five years of alcohol de-addiction services in a tertiary care general hospital. Indian J Psychiatry (2001) 0.87
Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes Brain Behav (2012) 0.86
Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037). Am J Drug Alcohol Abuse (2011) 0.85
Combining motivational interviewing with compliance enhancement therapy (MI-CET): development and preliminary evaluation of a new, manual-guided psychosocial adjunct to alcohol-dependence pharmacotherapy. J Stud Alcohol Drugs (2010) 0.85
A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. Drug Alcohol Depend (2011) 0.85
Gender differences in clinical outcomes for cocaine dependence: randomized clinical trials of behavioral therapy and disulfiram. Drug Alcohol Depend (2014) 0.84
Determination of GABA, glutamate and carbamathione in brain microdialysis samples by capillary electrophoresis with fluorescence detection. Electrophoresis (2011) 0.84
Disulfiram enhances subjective effects of dextroamphetamine in humans. Pharmacol Biochem Behav (2008) 0.84
Dopamine-beta hydroxylase polymorphism and cocaine addiction. Behav Brain Funct (2008) 0.83
Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat (2007) 0.83
Future pharmacological treatments for substance use disorders. Br J Clin Pharmacol (2014) 0.83
The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. Drug Alcohol Depend (2013) 0.83
Effects of disulfiram and dopamine beta-hydroxylase knockout on cocaine-induced seizures. Pharmacol Biochem Behav (2008) 0.82
LC-MS/MS method for the determination of carbamathione in human plasma. J Pharm Biomed Anal (2010) 0.82
Is level of exposure to a 12-step facilitation therapy associated with treatment outcome? J Subst Abuse Treat (2014) 0.82
12-step interventions and mutual support programs for substance use disorders: an overview. Soc Work Public Health (2013) 0.82
A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug Alcohol Depend (2016) 0.82
Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys. J Pharmacol Exp Ther (2014) 0.81
Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane Review. Syst Rev (2013) 0.81
What happens in treatment doesn't stay in treatment: cocaine abstinence during treatment is associated with fewer problems at follow-up. J Consult Clin Psychol (2014) 0.81
Examining differential effects of psychosocial treatments for cocaine dependence: an application of latent trajectory analyses. Drug Alcohol Depend (2009) 0.81
S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study. Neuropharmacology (2013) 0.81
Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice. Ann N Y Acad Sci (2014) 0.81
Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial. Drug Alcohol Depend (2012) 0.80
Chronic inhibition of dopamine β-hydroxylase facilitates behavioral responses to cocaine in mice. PLoS One (2012) 0.80
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. Eur Neuropsychopharmacol (2013) 0.80
New medications for the treatment of cocaine dependence. Psychiatry (Edgmont) (2005) 0.80
ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics (2013) 0.79
Therapeutic options and challenges for substances of abuse. Dialogues Clin Neurosci (2007) 0.79
A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend (2015) 0.79
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Res Health (2008) 0.78
Prompted to treatment by the criminal justice system: Relationships with treatment retention and outcome among cocaine users. Am J Addict (2015) 0.78
The relationship of therapeutic alliance and treatment delivery fidelity with treatment retention in a multisite trial of twelve-step facilitation. Psychol Addict Behav (2014) 0.78
Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients. J Subst Abuse Treat (2004) 0.78
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Am J Addict (2014) 0.77
Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature. Br J Clin Pharmacol (2014) 0.77
Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry (2015) 0.76
Serotonergic gene variation in substance use pharmacotherapy: a systematic review. Pharmacogenomics (2015) 0.76
Smokers versus snorters: do treatment outcomes differ according to route of cocaine administration? Exp Clin Psychopharmacol (2013) 0.76
Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet (2015) 0.76
Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.76
Patient Pre-Treatment Expectations Do Not Predict Cocaine Use Outcomes: Data From Four Clinical Trials. Subst Use Misuse (2016) 0.75
Alcohol use in opioid agonist treatment. Addict Sci Clin Pract (2016) 0.75
The MTHFR C677T Variant is Associated with Responsiveness to Disulfiram Treatment for Cocaine Dependency. Front Psychiatry (2013) 0.75
A general system for evaluating therapist adherence and competence in psychotherapy research in the addictions. Drug Alcohol Depend (2000) 4.92
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry (1994) 3.20
Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry (2001) 2.29
One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction (2000) 1.93
Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry (1994) 1.81
Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction (2000) 1.66
Contribution of the therapeutic alliance to outcome in active versus control psychotherapies. J Consult Clin Psychol (1997) 1.42
Comorbid psychopathology in binge eating disorder: relation to eating disorder severity at baseline and following treatment. J Consult Clin Psychol (2000) 1.40
Perspective is everything: the predictive validity of six working alliance instruments. J Psychother Pract Res (2001) 1.16
A sibling study of sensation seeking and opiate addiction. J Nerv Ment Dis (1994) 1.13
Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement. J R Soc Interface (2014) 1.01
'Research' versus 'real-world' patients: representativeness of participants in clinical trials of treatments for cocaine dependence. Drug Alcohol Depend (1999) 1.00
Blind man's bluff: effectiveness and significance of psychotherapy and pharmacotherapy blinding procedures in a clinical trial. J Consult Clin Psychol (1994) 0.97
Toxicity of methyl testosterone in the beagle dog. Toxicology (1977) 0.93
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend (1998) 0.91
Generalizability of the type A/type B distinction across different psychoactive substances. Am J Drug Alcohol Abuse (1996) 0.89
Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. J Nerv Ment Dis (1995) 0.85
Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl) (1995) 0.82
A comparison of alternate systems for diagnosing antisocial personality disorder in cocaine abusers. J Nerv Ment Dis (1993) 0.80
Variability in treatment-seeking cocaine abusers: implications for clinical pharmacotherapy trials. NIDA Res Monogr (1997) 0.80
Concurrent and predictive validity of antisocial personality disorder subtyping among substance abusers. J Nerv Ment Dis (1999) 0.79
Results of open reduction and cortico-cancellous autograft of intra-articular calcaneal fractures according to Palmer. Rev Chir Orthop Reparatrice Appar Mot (2008) 0.79
[Results of open reduction and cortico-cancellous autograft of intra-articular calcaneal fractures according to Palmer]. Rev Chir Orthop Reparatrice Appar Mot (2008) 0.79
[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl) (1998) 0.79
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) (2009) 0.78
Types of abuse and cocaine use in pregnant women. J Subst Abuse Treat (1998) 0.77
[Role of bone substitutes in reconstructions of the femur after revision of hip prosthesis]. Rev Chir Orthop Reparatrice Appar Mot (2000) 0.75
The intravenous toxicity of dibekacin sulphate (DKB) to female beagle dogs. Jpn J Antibiot (1980) 0.75
Integrating psychotherapy and pharmacotherapy for cocaine dependence: results from a randomized clinical trial. NIDA Res Monogr (1995) 0.75
An unreported cause of early postoperative dislocation following total hip revision: massive intra-capsular oedema related to inferior vena cava filter thrombosis. Orthop Traumatol Surg Res (2013) 0.75